معرفی
Dr. Simon Bridge is a Research Fellow at Newcastle University specializing in Hepatitis C virus (HCV) pathogenesis with a focus on viral interactions with host lipid metabolism. His research examines how HCV exploits apolipoprotein pathways to form lipoviral particles, directly influencing insulin resistance, metabolic syndrome, and treatment outcomes.
His work centers on:
- Genotype-specific modulation of lipid pathways (particularly genotypes 1 and 3)
- Role of apolipoproteins E and B in lipoviral particle assembly
- Mechanisms linking hypocholesterolemia to viral persistence
- Insulin resistance as a biomarker for treatment response
- Development of lipoviral particle quantification as superior diagnostic tools
Analysis of his 2010-2013 publications reveals consistent methodological approaches including intralipid infusion challenges, lipoprotein density fractionation, and clinical correlation studies. His research demonstrates that low-density apolipoprotein B-associated lipoviral particles—not total viral load—provide critical clinical insights for genotype 1 infection, while genotype 3 uniquely disrupts cholesterol production pathways. These findings established foundational knowledge for host-targeted HCV therapeutics.
Dr. Bridge collaborates extensively within Newcastle University's medical research ecosystem, particularly with Professor Margaret Bassendine's hepatology group, Dr. David Sheridan's virology team, and Emeritus Professor Geoffrey Toms' metabolic research unit. His work bridges basic virology and clinical hepatology through rigorous biochemical and patient-based investigations.
حوزههای پژوهشی
